https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Nihon Geka Gakkai Zasshi 2002 Apr;103(4):376-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Nihon Geka Gakkai Zasshi 2002 Apr;103(4):376-802002-04-01 00:00:002002-04-01 00:00:00[Immunotherapy for esophageal carcinoma]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Minerva Ginecol 2002 Apr;54(2):133-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Minerva Ginecol 2002 Apr;54(2):133-442002-04-01 00:00:002002-04-01 00:00:00Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Haematologica 2002 Apr;87(4):400-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Haematologica 2002 Apr;87(4):400-72002-04-01 00:00:002019-02-15 09:25:49Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2002-04-01 / Blood 2002 Apr;99(7):2512-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2002-04-01 / Blood 2002 Apr;99(7):2512-72002-04-01 00:00:002019-02-15 08:51:11Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12
